New Delhi, Sept. 27 -- In a sweeping new trade policy move, U.S. President Donald Trump has announced a 100 per cent tariff on all branded and patented pharmaceutical products imported into the United States, effective October 1. India, a major exporter of generic drugs and Active Pharmaceutical Ingredients (APIs), may see a limited impact - at least for now. The new measure targets only patented and branded medications, which form a smaller share of India's pharma exports to the US. However, the administration introduced a key exemption: companies actively building pharmaceutical manufacturing facilities in the US will not be subject to the tariff.

According to Trump, this includes firms that have "broken ground" or are "under construct...